Amarin (AMRN) Scheduled to Post Earnings on Wednesday

Amarin (NASDAQ:AMRN) is scheduled to be announcing its earnings results after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Amarin Stock Performance

Shares of AMRN opened at $0.58 on Wednesday. The firm has a market cap of $237.37 million, a P/E ratio of -4.82 and a beta of 1.92. Amarin has a 12 month low of $0.57 and a 12 month high of $1.37. The stock’s 50 day moving average is $0.60 and its two-hundred day moving average is $0.73.

Insider Activity at Amarin

In other news, CEO Aaron Berg acquired 160,000 shares of the business’s stock in a transaction on Friday, August 2nd. The stock was bought at an average cost of $0.64 per share, for a total transaction of $102,400.00. Following the purchase, the chief executive officer now owns 805,380 shares in the company, valued at approximately $515,443.20. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.96% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Amarin from a “buy” rating to a “hold” rating in a research note on Thursday, July 4th.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.